Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 15,142 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

NCT07321678
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
ASC30 tablets, Placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
8
States / cities
Riverside, California • San Jose, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 5:58 AM EDT
Not listed Phase 2 Interventional

A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease

NCT05607615
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Hydroxypropyl Beta Cyclodextrin, Placebo
Drug
Lead sponsor
Cyclo Therapeutics, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Brooksville, Florida • Winter Park, Florida • Marrero, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination

NCT00889889
View directory record Official record
Conditions
Influenza
Interventions
Cell-Derived Trivalent Subunit Influenza Vaccine, Placebo
Biological
Lead sponsor
Abbott Biologicals
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
15
States / cities
Jacksonville, Florida • Pembroke Pines, Florida • South Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 31, 2026, 5:58 AM EDT
Not listed Phase 2 Interventional

A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes

NCT02312050
View directory record Official record
Conditions
Diabetic Chronic Kidney Disease
Interventions
GCS-100, Placebo
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years to 90 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Chula Vista, California • El Centro, California • La Jolla, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 31, 2026, 5:58 AM EDT
Recruiting Phase 2 Interventional

Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

NCT07527650
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, T2DM
Interventions
HM15275, Placebo of HM15275
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
20
States / cities
Mesa, Arizona • Santa Clarita, California • DeLand, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia

NCT05478174
View directory record Official record
Conditions
General Anesthesia
Interventions
HSK3486, Propofol
Drug
Lead sponsor
Haisco-USA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
23
States / cities
Sheffield, Alabama • Phoenix, Arizona • Davis, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 31, 2026, 5:58 AM EDT
Withdrawn Not applicable Interventional

Single Shot Infraclavicular Brachial Plexus Block vs Local Infiltration After Wrist Arthroscopy Surgery

NCT02970097
View directory record Official record
Conditions
Wrist Injuries, Postoperative Pain Control
Interventions
20ml bolus of 0.5% ropivicaine, 10 ml of 0.5% ropivicaine, Midazolam, Fentanyl
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 31, 2026, 5:58 AM EDT
Recruiting Phase 2 Interventional

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

NCT07527910
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions
ALN-PNP, Tirzepatide, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
9
States / cities
Tucson, Arizona • Coronado, California • Pasadena, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

NCT01777152
View directory record Official record
Conditions
Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma
Interventions
brentuximab vedotin, doxorubicin, prednisone, vincristine, cyclophosphamide
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
32
States / cities
Gilbert, Arizona • Duarte, California • Stanford, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 31, 2026, 5:58 AM EDT
Terminated Phase 3 Interventional Results available

Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects

NCT04084678
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
Ralinepag, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Tucson, Arizona • Aurora, Colorado • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers

NCT03492385
View directory record Official record
Conditions
Healthy
Interventions
PB2452 Infusion, Placebo - Sodium Chloride, Ticagrelor Oral Tablet - Pre-Treatment, Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
Drug
Lead sponsor
SFJ Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 31, 2026, 5:58 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

NCT05403385
View directory record Official record
Conditions
Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
Interventions
inupadenant, Placebo, Carboplatin, Pemetrexed
Drug
Lead sponsor
iTeos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Fayetteville, Arkansas • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Initiating Early Control of Migraine Pain and Associated Symptoms

NCT04163185
View directory record Official record
Conditions
Migraine
Interventions
AXS-07 (MoSEIC meloxicam and rizatriptan), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Colton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema

NCT00656643
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Sirolimus, Placebo
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

NCT00549718
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
21
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients

NCT00795418
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, CAD106
Biological
Lead sponsor
Novartis
Industry
Eligibility
40 Years to 85 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

NCT01270841
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Placebo, topical testosterone, Androxal
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
18
States / cities
Garden Grove, California • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 31, 2026, 5:58 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Hair Stimulating Complex (HSC) in Female Pattern Hair Loss

NCT03662854
View directory record Official record
Conditions
Alopecia
Interventions
Hair Stimulating Complex (HSC), Phosphate Buffered Saline
Biological · Other
Lead sponsor
Histogen
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 3 Interventional

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

NCT04930094
View directory record Official record
Conditions
Giant Cell Arteritis (GCA)
Interventions
Secukinumab 300 mg, Placebo, Secukinumab 150 mg
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 100 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Los Angeles, California • Plantation, Florida • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss

NCT02345031
View directory record Official record
Conditions
Age-Related Hearing Loss
Interventions
AUT00063, Placebo
Drug
Lead sponsor
Autifony Therapeutics Limited
Industry
Eligibility
50 Years to 89 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Sacramento, California • Colorado Springs, Colorado • Boca Raton, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia

NCT04435431
View directory record Official record
Conditions
Parkinson Disease
Interventions
Mesdopetam, Placebo
Drug
Lead sponsor
Integrative Research Laboratories AB
Industry
Eligibility
30 Years to 79 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
14
States / cities
Scottsdale, Arizona • Long Beach, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Online Expert Peer Facilitation of the EVERYbody Project

NCT05336253
View directory record Official record
Conditions
Body Image, Eating Disorder Symptom, Weight Bias
Interventions
EVERYbody Project-Connect, Self-Help Workbook
Behavioral
Lead sponsor
Western Washington University
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bellingham, Washington
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 31, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations

NCT03670953
View directory record Official record
Conditions
Parkinson's Disease (Disorder)
Interventions
IR CD-LD, IPX203 ER CD-LD, Placebo Matching IPX203, Placebo Matching IR CD-LD
Drug · Other
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
40 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
56
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 31, 2026, 5:58 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis

NCT02376972
View directory record Official record
Conditions
BACTERIAL VAGINOSIS
Interventions
RIFAXIMIN VAGINAL TABLET 25 MG, RIFAXIMIN VAGINAL TABLET 100 MG, PLACEBO VAGINAL TABLET, METROGEL VAGINAL
Drug
Lead sponsor
Alfasigma S.p.A.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Oct 31, 2026, 5:58 AM EDT